ModifiedPremera BluecrossPolicy N/A

Upper gastrointestinal (UGI) endoscopy (esophagogastroduodenoscopy, EGD) - Coverage Criteria In Adults

Medical necessity and site-of-service criteria for elective diagnostic and therapeutic upper GI endoscopy in individuals aged 19 and older; describes covered indications, not medically necessary situations, documentation, and coding guidance for providers.

Policy Summary

PayerPremera Bluecross

PolicyUpper gastrointestinal (UGI) endoscopy (esophagogastroduodenoscopy, EGD) - Coverage Criteria In Adults

Policy CodePolicy N/A

Change TypeMaterial revisions to indications, surveillance, and site-of-service criteria

Effective DateJul. 1, 2026

Next Review DateN/A

Key ActionDocument presence of alarm symptoms or failure of an appropriate PPI trial when requesting upper endoscopy.

SourceLink

POLICY UPDATE CHANGES

Changed policy title from 'for Adults' to 'In Adults' and added Site of Service Ambulatory Service Center (ASC) Select Diagnostic or Surgical Procedures criteria; effective for dates of service on or after March 4, 2026 (later moved to July 1, 2026).

UGI considered not medically necessary for confirming Helicobacter pylori eradication.

Specified BE (Barrett's esophagus) surveillance schedule for low grade dysplasia: repeat UGI at 6 months, then surveillance at 12 months and annually thereafter.

Modified UGI medically necessary statement for GERD or dyspepsia to require symptoms that persist despite 8 weeks of continuous daily PPI therapy OR evaluation of symptoms that returned after PPI discontinuation.

UGI is considered medically necessary when performed for endoscopic ultrasound guided fine needle aspiration/biopsy(s) of adjacent organs or structures.

19+policy applies to individuals aged

Jul. 1, 2026effective date listed

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

8 wksEmpiric PPI trial duration before endoscopy

6 morepeat UGI interval for BE (low grade)

43235,43238,43239,43242example CPT codes included

Coverage Criteria for Upper Gastrointestinal Endoscopy (UGI/EGD)

Medical Necessity Criteria

Covered when ALL of the following apply depending on indication groups below

Malignant indications: UGI endoscopy is medically necessary for malignant indications including Barrett esophagus, dysplasia, esophageal cancer, familial adenomatous polyposis (FAP), gastric cancer, head/neck cancer, and history of Lynch syndrome/HNPCC.

Alarm symptoms: UGI endoscopy is medically necessary for evaluation of ANY alarm symptom: iron deficiency anemia; GI bleeding; epigastric mass on exam or abnormal barium/x-ray; persistent vomiting including hematemesis; dysphagia; or unintentional weight loss ≥3 kg since symptom onset.weight loss ≥3 kg

High-risk non-malignant follow-up/therapeutic indications: Includes evaluation or treatment of suspected portal hypertension/cirrhosis (screening for and treatment of esophageal varices), therapeutic banding or sclerotherapy of varices with surveillance until eradication then 1–3 months and every 6–12 months thereafter, treatment of bleeding lesions (e.g., ulcers), follow-up of eosinophilic or erosive esophagitis (including assessment after a 2-month PPI course), suspected Crohn disease involving the upper GI, foreign body removal, ulcer confirmation when conservative therapy failed or is contraindicated, follow-up UGI every 2 months until ulcer healing, pre-transplant evaluation, endoscopic ultrasound–guided FNA/biopsy, and post cardiac ablation evaluation.

Variceal surveillance: repeat until eradication, then 1–3 months after eradication, then every 6–12 months

GERD / dyspepsia: UGI endoscopy is medically necessary when GERD or dyspepsia symptoms have been present for at least 3 months AND persist despite 8 weeks of continuous daily PPI therapy, OR for evaluation of return of symptoms after PPI discontinuation.≥3 months symptoms AND 8 weeks continuous PPI

Barrett esophagus surveillance: Surveillance intervals based on pathology: high-grade dysplasia — repeat every 3 months for 1 year then annually; low-grade dysplasia — repeat at 6 months, then at 12 months and annually thereafter; no dysplasia (metaplasia) — repeat once within 12 months after initial biopsy then every 3 years if unchanged.

Screening in cirrhosis: At initial diagnosis of cirrhosis perform one UGI endoscopy to screen for esophageal varices, then no more frequently than annually for ongoing screening.

Other covered indications: Includes achalasia evaluation, evaluation for small-bowel disease (e.g., celiac disease), preoperative evaluation prior to bariatric surgery (unless bariatric surgery is contractually excluded), evaluation for newly diagnosed (within one year) pernicious anemia, and screening for Barrett in males ≥50 years with ≥5 years of GERD symptoms and ≥1 additional risk factor.male ≥50 years with ≥5 years GERD and ≥1 risk factor

Appropriate Indications for Upper Endoscopy (EGD)

Covered when ONE of the following indication groups is documented per cited society guidance:

Alarm symptoms: Presence of any alarm symptom: anemia, bleeding, dysphagia, recurrent vomiting, or weight loss.

ACP Best Practice Advice 1

Refractory GERD: Typical GERD symptoms that persist despite an appropriate therapeutic trial of PPI therapy (4–8 weeks or 8 weeks once daily) or symptoms that return when PPIs are discontinued.PPI 4-8 weeks or 8 weeks as noted

ACG and ACP recommendations

Severe erosive esophagitis follow-up: Severe erosive esophagitis after a 2-month PPI course to assess healing and exclude Barrett esophagus.2 months PPI

ACP Best Practice Advice 2

Referenced coverage statements and historical updates

Medicare and policy-level coverage statements referenced in this segment

Medicare NCD coverage: Endoscopic procedures are covered when reasonable and necessary for the individual patient (CMS NCD 100.2).reasonable and necessary

UGI medically necessary examples (referenced in history notes): The policy history and review notes reference medically necessary determinations over time including surveillance of Barrett esophagus (intervals updated), therapeutic banding/sclerotherapy of esophageal varices, UGI prior to bariatric surgery (changed from not medically necessary to medically necessary), inclusion of EUS-guided FNA/biopsy indications, and follow-up UGI for healing ulcers every 2 months until healed.condition-specific

Selected coverage statements

Selected coverage statements and surveillance criteria updated in history:

GERD/dyspepsia UGI indication: UGI is considered medically necessary for GERD or dyspepsia symptoms that persist despite 8 weeks of continuous daily PPI therapy OR for evaluation of GERD/dyspepsia symptoms that have returned after PPI therapy has been discontinued.8 weeks PPI

chunk 54

Barrett's esophagus - low grade dysplasia surveillance: Repeat UGI at 6 months, then surveillance at 12 months and annually thereafter for low grade dysplasia; criteria for other grades of dysplasia were removed in the 03/01/24 update.6 months then 12 months then annually

chunk 55

Endoscopic ultrasound-guided FNA/biopsy indication: UGI is considered medically necessary when performed for endoscopic ultrasound guided fine needle aspiration/biopsy(s) of adjacent organs or structures (e.g., esophagus, stomach, duodenum, pancreas, liver).

Upper gastrointestinal (UGI) endoscopy (EGD) is not medically necessary when performed for evaluation of symptoms that are chronic, non-progressive, atypical for known organic disease, and considered functional in origin (with rare one-time exams as exceptions to exclude organic disease when symptoms are unresponsive to therapy). Other examples of situations considered not medically necessary include: evaluation of uncomplicated heartburn that responds to conservative medical management; procedures that will not alter patient management; follow-up of certain asymptomatic or uncomplicated radiographic findings (e.g., deformed duodenal bulb asymptomatic or responsive to therapy, uncomplicated duodenal ulcer that has responded to therapy, asymptomatic sliding hiatal hernia); routine screening in the absence of a clinical indication; and surveillance of healed benign disease (such as healed gastric or duodenal ulcer).

Esophagogastroduodenoscopy (EGD) is generally not indicated for symptoms considered functional in origin, except when a single endoscopic examination is performed to exclude organic disease (for example, when symptoms do not respond to therapy). The ASGE guidance cited also lists other non-indicated scenarios such as metastatic adenocarcinoma when results will not change management and radiographic findings that are asymptomatic or uncomplicated (sliding hiatal hernia, uncomplicated duodenal ulcer, deformed duodenal bulb) as situations where EGD is usually unnecessary.

Historically, the policy included a statement that UGI prior to bariatric surgery was not medically necessary when bariatric surgery itself was contractually excluded. That wording was subsequently changed in later history entries: the policy has been revised over time with updates to the bariatric surgery statement (see history notes) reflecting that the earlier 'not medically necessary for bariatric surgery' language was removed or modified as the policy was reinstated and updated.

UGI endoscopy is explicitly considered not medically necessary for the purpose of confirming Helicobacter pylori eradication. This policy statement was added in the history updates and should be used to deny or not authorize endoscopy performed solely to confirm eradication.

UGI endoscopy is considered not medically necessary whenever the documented clinical indications in this policy are not met. Examples include functional non-progressive symptoms, uncomplicated heartburn responsive to conservative care, procedures unlikely to alter management, asymptomatic radiographic findings, routine screening without clinical indication, and surveillance of healed benign disease. Providers should confirm that the requested procedure meets a stated medical necessity indication before authorization.

Routine sequential or periodic EGD is generally not indicated for surveillance of healed benign disease or for many gastric premalignant conditions listed by ASGE (for example, gastric atrophy, pernicious anemia, fundic gland or hyperplastic polyps, gastric intestinal metaplasia) unless a change in clinical status or specific surveillance indication is documented. ASGE guidance specifically identifies surveillance of healed benign disease and routine repeat EGD during repetitive dilation of benign strictures (without change in status) as generally unnecessary.

Surveillance endoscopy for individuals with Barrett esophagus and low-grade dysplasia is stated as: repeat UGI at 6 months, then surveillance at 12 months and annually thereafter. This surveillance schedule was added in the policy history and replaces prior broader or unspecified dysplasia surveillance statements.

The policy history includes a specific addition clarifying that UGI is not medically necessary for confirming Helicobacter pylori eradication. This explicit statement was added in the 09/01/25 history update and should be applied when UGI is requested solely for eradication confirmation.

Coding and Procedure Codes

Covered CPT CodesCPTCovered

43235	Esophagogastroduodenoscopy, flexible, transoral; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure).
43238	Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound- guided intramural or transmural fine needle aspiration/biopsy(s), (includes endoscopic ultrasound examination limited to the esophagus, stomach or duodenum, and adjacent structures).
43239	Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple.
43242	Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound- guided intramural or transmural fine needle aspiration/biopsy(s) (includes endoscopic ultrasound examination of the esophagus, stomach, and either the duodenum or a surgically altered stomach where the jejunum is examined distal to the anastomosis).

CPT codes mentioned in historyCPT

43233	CPT code referenced as added (2014)
43253	CPT code referenced as added (2014)
43254	CPT code referenced as added (2014)
43266	CPT code referenced as added (2014)
43270	CPT code referenced as added (2014)
43252	CPT code removed from policy in 2013 as it pertains to another policy
43236	CPT code removed from policy (2015 history note)

Informational CPT codes removedCPT

43233-43234, 43237, 43240-43241, 43243-43256, 43258-43259, 43270

Informational CPT codes removed

Diagnosis code removalICD-10

ICD-9 codes

Removed from policy (historical)

Diagnosis code removal - supporting historyCPT

43252

CPT code removed from policy in 2013 as it pertains to another policy

BE surveillance interval — low grade dysplasia

Surveillance schedule for BE with low-grade dysplasiaRepeat upper GI endoscopy at 6 months, then at 12 months, then annually thereafter.

Removed other dysplasia gradesPolicy history notes indicate criteria for other grades of dysplasia were removed (03/01/24).

Source of changeChange recorded in 03/01/24 history entry clarifying BE surveillance intervals for low-grade dysplasia.

PPI therapy duration requirement

Minimum PPI trial duration>= 8 weeks of continuous daily proton pump inhibitor (PPI) therapy before UGI is considered medically necessary for GERD or dyspepsia.

Provider Actions, Authorization, and Documentation

Prior Authorization

Medical necessity and site-of-service review

Elective diagnostic and surgical upper GI (UGI) procedures require prior review for medical necessity and site-of-service appropriateness. Site-of-service will be evaluated (ambulatory surgical center, off‑campus outpatient hospital/medical center, on‑campus outpatient hospital/medical center, or inpatient hospital/medical center). Procedures should be performed in the most appropriate, safe, and cost‑effective site; hospital outpatient settings may be considered when no qualifying ASC is available within 30 miles, the ASC lacks necessary equipment or physician privileges, ASC-specific guidelines prohibit use for the individual, the patient is aged 18 or younger, or the procedure is performed with another service that requires a hospital outpatient department. Individuals with clinical conditions that increase risk for complications (for example ASA III+, significant cardiac, pulmonary, liver, renal risks, bleeding disorders, anticipated transfusion) may require a higher‑acuity site. Note: site-of-service review does not apply to Indian Health Services (IHS) facilities.

Site-of-service criteria apply to elective diagnostic/surgical UGI procedures
ASC is preferred when criteria are met; hospital outpatient or inpatient only when justified

Prior Authorization

Clinical indications required for authorization

Background and Definitions

Upper gastrointestinal endoscopy (EGD/UGI) inspects the esophagus, stomach, and duodenum using a flexible endoscope and is used to evaluate causes of heartburn, dysphagia, vomiting, bleeding, to remove polyps or foreign bodies, obtain biopsies, and perform therapeutic interventions such as banding of varices or dilation of strictures. Professional society guidance cited in the policy emphasizes conservative medical management before invasive testing when cancer is not suspected and restricts endoscopy to indications expected to alter management.

Barrett esophagus — definition and clinical relevance

DefinitionBarrett esophagus: replacement of normal squamous esophageal epithelium by metaplastic columnar or glandular epithelium due to GERD.

Clinical relevanceThis metaplastic change predisposes the individual to esophageal adenocarcinoma and guides surveillance recommendations.

Surveillance implicationPolicy specifies surveillance intervals by dysplasia grade (e.g., low-grade dysplasia: 6 months, then 12 months, then annually).

EGD (Esophagogastroduodenoscopy) — definition

Policy Summary

PayerPremera Bluecross

PolicyUpper gastrointestinal (UGI) endoscopy (esophagogastroduodenoscopy, EGD) - Coverage Criteria In Adults

Policy CodePolicy N/A

Change TypeMaterial revisions to indications, surveillance, and site-of-service criteria

Effective DateJul. 1, 2026

Next Review DateN/A

Key ActionDocument presence of alarm symptoms or failure of an appropriate PPI trial when requesting upper endoscopy.

SourceLink

On This Page

Non-cardiac chest pain: Chest pain after cardiac causes excluded when objective testing for GERD (endoscopy and/or reflux monitoring) is recommended.cardiac workup negative

ACG guidance

Dysphagia or alarm features at presentation: Patients presenting with dysphagia or other alarm symptoms (weight loss, GI bleeding) — endoscopy is recommended as first test.

ACG recommendation

Barrett esophagus surveillance: Surveillance endoscopy for Barrett esophagus stratified by dysplasia: no dysplasia every 3–5 years; low-grade dysplasia with therapy or surveillance at approximately 12 months; high-grade dysplasia managed with endoscopic therapy.no dysplasia 3-5 years; low-grade ~12 months; high-grade therapy

ACG and international taskforce guidance

Other ASGE indications: EGD indicated for persistent upper abdominal symptoms despite therapy, upper abdominal symptoms with signs suggesting organic disease, persistent vomiting of unknown cause, suspected neoplastic lesion, surveillance for premalignant conditions, GI bleeding evaluation, tissue sampling when indicated, PEG/feeding tube placement, dilation, foreign body removal, and specified therapeutic interventions per ASGE SOP.

ASGE SOP lists multiple indications and non-indications

Esophageal varices therapy: Therapeutic banding (ligation) or sclerotherapy of esophageal varices is considered medically necessary with surveillance intervals specified in policy history.

chunk 54

UGI not for H. pylori eradication confirmation: UGI is considered not medically necessary for confirming Helicobacter pylori eradication.

chunk 56

Context for PPI requirementUGI may also be indicated if symptoms return after PPI discontinuation; H2 blocker statements were removed from policy.

Documentation expectationClinical notes should document an appropriate PPI trial (commonly 4–8 weeks or 8 weeks as per society guidance) when requesting endoscopy for GERD.

Prior authorization must document clinical indications that meet medical necessity. Authorization is supported when individuals have: alarm symptoms (anemia, bleeding, dysphagia, recurrent vomiting, unintentional weight loss); known or suspected malignant indications; high‑risk non‑malignant conditions requiring follow up or treatment (examples: portal hypertension/cirrhosis, eosinophilic esophagitis, erosive esophagitis, esophageal varices, history of gastric surgery, symptomatic strictures, persistent unexplained anorexia or significant swallowing difficulty); or other indications described in policy (e.g., evaluation of diarrhea when small‑bowel disease or IBD suspected, UGI tract obstruction/stricture, treatment of bleeding lesions). UGI is not medically necessary for confirming H. pylori eradication, routine screening without clinical indication, for functional non‑progressive symptoms absent red flags, or when endoscopy will not change management.

Alarm symptoms required for authorization: anemia, bleeding, dysphagia, recurrent vomiting, weight loss
Not medically necessary: routine screening, confirmation of H. pylori eradication, functional non‑progressive symptoms without alarm features

Note

Medicare reasonable and necessary

For Medicare enrollees, coverage of endoscopic procedures is limited to those that are reasonable and necessary per the Medicare National Coverage Determinations (NCD). Determinations must meet Medicare’s reasonable and necessary criteria in addition to this policy’s clinical criteria.

Apply Medicare NCD reasonable and necessary standard for Medicare patients

Note

Effective date and authorization

This policy (including changes to ASC/site‑of‑service criteria) is effective July 1, 2026. Prior authorization and any new site‑of‑service requirements apply to dates of service on or after the effective date following provider notification.

Effective date: Jul. 1, 2026
Provider notification provided prior to effective date

Documentation Required

Conservative management before endoscopy

Conservative medical management should be attempted before invasive UGI endoscopy for non‑alarm GERD/dyspepsia presentations. Professional guidance supports an empiric PPI trial prior to diagnostic endoscopy for classic GERD symptoms without alarm features.

Conservative management recommended before invasive testing
Failure to pursue conservative management may be a basis for denial

Step Therapy

PPI trial before endoscopy

For GERD or dyspepsia (without alarm features) a trial of 8 weeks of continuous daily proton pump inhibitor (PPI) therapy is required and should be documented prior to authorization. If PPIs are contraindicated or not tolerated, a standard‑dose H2RA trial may be acceptable as documented in the policy.

Required PPI trial: 8 weeks continuous daily PPI before diagnostic UGI for GERD/dyspepsia
H2RA acceptable only if PPI contraindicated/intolerant

Documentation Required

Required clinical documentation

Clinical documentation submitted with authorization must include, for individuals aged 19 and older: presence of malignant indications or any alarm symptom; description of high‑risk non‑malignant conditions requiring follow up/treatment; duration and response to prior therapies (including exact PPI regimen and dates showing an 8‑week continuous daily trial when applicable); relevant prior test results and prior endoscopy findings if available; and the specific reason the procedure is expected to alter management. Reference is made to the Documentation Requirements section for full documentation expectations.

Document alarm symptoms or malignant indications
Document prior therapy including start/end dates for PPI trial and response
Refer to Documentation Requirements section for complete list

TermEsophagogastroduodenoscopy (EGD): upper gastrointestinal endoscopy; a procedure examining the esophagus, stomach, and duodenum using a flexible endoscope.

Typical usesUsed to evaluate causes of severe heartburn, dysphagia, persistent vomiting, and GI bleeding; may include biopsy or therapeutic interventions.

SedationUsually performed under light intravenous sedation.

UGI endoscopy / EGD — definition

Procedure nameUpper gastrointestinal (UGI) endoscopy (esophagogastroduodenoscopy, EGD): visualization of the esophagus, stomach, and upper duodenum via a flexible endoscope inserted through the mouth.

Primary purposePrimarily a diagnostic tool to identify causes of upper GI symptoms and to obtain biopsies; some therapeutic procedures (e.g., polyp removal) can be performed.

Typical indicationsInvestigation of severe heartburn (dyspepsia), dysphagia, GERD, persistent vomiting, and frank GI bleeding.

Non-cardiac chest pain (NCCP) — definition

DefinitionNon-cardiac chest pain (NCCP): chest pain resembling angina in individuals whose cardiac workup has excluded heart disease.

Relevance to GI evaluationWhen cardiac causes are excluded, NCCP may prompt GI evaluation because esophageal conditions can mimic cardiac pain.

GuidanceACG recommends excluding a cardiac cause before commencing gastrointestinal evaluation for chest pain.

UGI / EGD — brief definition excerpt

Brief definitionUGI/EGD: flexible endoscopic procedure inserted through the mouth to visualize the esophagus, stomach, and duodenum; used for diagnostic and therapeutic evaluation.

Examples of therapeutic useRemoval of polyps, hemostatic treatment of bleeding lesions, and sampling via biopsy or EUS-guided FNA.

Sedation and settingUsually performed with light IV sedation; elective procedures subject to medical necessity and site-of-service review.

Barrett's esophagus (BE) surveillance — low grade dysplasia

Recommended surveillance intervalRepeat UGI at 6 months, then at 12 months, then annually thereafter for Barrett's esophagus with low-grade dysplasia.

Policy historyThis specific BE low-grade dysplasia surveillance schedule was added in the 03/01/24 policy revision.

ApplicabilityApplies to surveillance of Barrett's esophagus when low-grade dysplasia is present on pathology.

PPI trial requirement before UGI for GERD/dyspepsia

PPI trial requirementUpper endoscopy for GERD or dyspepsia is considered medically necessary only if symptoms persist despite 8 weeks of continuous daily PPI therapy or for evaluation of symptoms that return after PPI discontinuation.

Society guidance contextThe policy aligns with recommendations that an empiric PPI trial (commonly 8 weeks once daily) is an initial step before diagnostic endoscopy for classic GERD without alarm features.

Documentation noteClinical documentation should record duration and response to PPI therapy when requesting UGI for GERD/dyspepsia.